New

Small Interfering RNA (siRNA) Therapeutics Market

2021

Small Interfering RNA (siRNA) Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Indication (Oncology, Cardiovascular Diseases, Respiratory Disorders, Neurodegenerative Disorders, Infectious Diseases, Other); Types (Liposome Based Systemic Therapy, Nanoparticle Based Systemic Therapy, Other); End User (Diagnostic Laboratory, Research and Academic Laboratories) and Geography

| Report Code: TIPRE00008765 | No. of Pages: 150 | Category: Healthcare IT | Status: Upcoming

Market Insights

Small Interfering RNA (siRNA) Therapeutics Market 2028 By Indication, Types, End User and Geography | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Small interfering RNA (siRNA) is a type of genetic medicine, also called silencing RNA, as it can silence any overexpressed genes in diseases. These are most widely used to assess the specific contributions of genes to a variety of cell phenotypes. The siRNAs help recognize novel pathways and validate targets for various life-threatening diseases such as cancer, AIDS, and hepatitis. The cells own enzymes process them to eliminate the mRNA of the target gene to prevent overexpression of the pathogenic gene. They are generally effective than other traditional medicines. The therapy includes liposome-based systemic therapy and nanoparticle-based systemic therapy.

MARKET SCOPE

The "Global Small Interfering RNA (siRNA) Therapeutics Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the small interfering RNA (siRNA) therapeutics market with detailed market segmentation by indication, types, end user, and geography. The report provides key statistics on the market status of the leading small interfering RNA (siRNA) therapeutics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •  Based on indication, the global small interfering RNA (siRNA) therapeutics market is segmented into oncology, cardiovascular diseases, respiratory disorders, neurodegenerative disorders, infectious diseases and other.
  •  Based on types, the market is segmented into liposome based systemic therapy, nanoparticle based systemic therapy and other.
  •  On the basis of end-users, the market is bifurcated into diagnostic laboratory, research and academic laboratories.

MARKET DYNAMICS
Drivers:

  •  High efficiency of the siRNA as compared to previous reverse genetic technologies.
  •  Rise in the number of clinical trials.
  •  Rise in the prevalence of cancer.
  •  The short time of pre-clinical development.
  •  Increase in the government funding for R&D activities.

Restraints:

  •  Stringent FDA regulations.
  •  Changing reimbursement policies.



Get more information on this report :

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The small interfering RNA (siRNA) therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the small interfering RNA (siRNA) therapeutics market in these regions.

IMPACT OF COVID-19 ON SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET

COVID-19 initially began in Wuhan (China) in December 2019, and till now, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The COVID-19 pandemic has impacted the worldwide economy at various levels and has become a threat to global health. Due to the shutdown of business units, shortage in the supply of raw materials, and labor, there was a decline in the sales of market players. The shutdown of plants and factories worldwide disturbed the manufacturing, delivery schedules, and product sales. Also, the travel bans imposed by countries affected business collaborations and partnership opportunities. This impacted the small interfering RNA (siRNA) therapeutics market growth. Therefore, the pandemic has significantly affected the market's development and its growth.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the small interfering RNA (siRNA) therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from small interfering RNA (siRNA) therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for small interfering RNA (siRNA) therapeutics in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the small interfering RNA (siRNA) therapeutics market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  Horizon Discovery
  •  GlaxoSmithKline
  •  Sirna Therapeutics, Inc.
  •  Alnylam Pharmaceuticals
  •  Sanofi Genzyme
  •  Olix Pharmaceuticals
  •  Silence Therapeutics AG
  •  Calando Pharmaceuticals
  •  Arbutus Biopharma Corp
  •  Sylentis S.A
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Small Interfering RNA (siRNA) Therapeutics Market - By Indication
1.3.2 Small Interfering RNA (siRNA) Therapeutics Market - By Types
1.3.3 Small Interfering RNA (siRNA) Therapeutics Market - By End User
1.3.4 Small Interfering RNA (siRNA) Therapeutics Market - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. SMALL INTERFERING RNA (SIRNA) THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. SMALL INTERFERING RNA (SIRNA) THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING

7. SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
7.1. OVERVIEW
7.2. INDICATION MARKET FORECASTS AND ANALYSIS
7.3. ONCOLOGY
7.3.1. Overview
7.3.2. Oncology Market Forecast and Analysis
7.4. CARDIOVASCULAR DISEASES
7.4.1. Overview
7.4.2. Cardiovascular Diseases Market Forecast and Analysis
7.5. RESPIRATORY DISORDERS
7.5.1. Overview
7.5.2. Respiratory Disorders Market Forecast and Analysis
7.6. NEURODEGENERATIVE DISORDERS
7.6.1. Overview
7.6.2. Neurodegenerative Disorders Market Forecast and Analysis
7.7. INFECTIOUS DISEASES
7.7.1. Overview
7.7.2. Infectious Diseases Market Forecast and Analysis
7.8. OTHER
7.8.1. Overview
7.8.2. Other Market Forecast and Analysis
8. SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - TYPES
8.1. OVERVIEW
8.2. TYPES MARKET FORECASTS AND ANALYSIS
8.3. LIPOSOME BASED SYSTEMIC THERAPY
8.3.1. Overview
8.3.2. Liposome Based Systemic Therapy Market Forecast and Analysis
8.4. NANOPARTICLE BASED SYSTEMIC THERAPY
8.4.1. Overview
8.4.2. Nanoparticle Based Systemic Therapy Market Forecast and Analysis
8.5. OTHER
8.5.1. Overview
8.5.2. Other Market Forecast and Analysis
9. SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. DIAGNOSTIC LABORATORY
9.3.1. Overview
9.3.2. Diagnostic Laboratory Market Forecast and Analysis
9.4. RESEARCH AND ACADEMIC LABORATORIES
9.4.1. Overview
9.4.2. Research and Academic Laboratories Market Forecast and Analysis

10. SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Small Interfering RNA (siRNA) Therapeutics Market Overview
10.1.2 North America Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis
10.1.3 North America Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Indication
10.1.4 North America Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Types
10.1.5 North America Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By End User
10.1.6 North America Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 Canada Small Interfering RNA (siRNA) Therapeutics Market
10.1.6.1.1 Canada Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.1.6.1.2 Canada Small Interfering RNA (siRNA) Therapeutics Market by Types
10.1.6.1.3 Canada Small Interfering RNA (siRNA) Therapeutics Market by End User
10.1.6.2 Mexico Small Interfering RNA (siRNA) Therapeutics Market
10.1.6.2.1 Mexico Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.1.6.2.2 Mexico Small Interfering RNA (siRNA) Therapeutics Market by Types
10.1.6.2.3 Mexico Small Interfering RNA (siRNA) Therapeutics Market by End User
10.1.6.3 US Small Interfering RNA (siRNA) Therapeutics Market
10.1.6.3.1 US Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.1.6.3.2 US Small Interfering RNA (siRNA) Therapeutics Market by Types
10.1.6.3.3 US Small Interfering RNA (siRNA) Therapeutics Market by End User
10.2. EUROPE
10.2.1 Europe Small Interfering RNA (siRNA) Therapeutics Market Overview
10.2.2 Europe Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis
10.2.3 Europe Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Indication
10.2.4 Europe Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Types
10.2.5 Europe Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By End User
10.2.6 Europe Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Small Interfering RNA (siRNA) Therapeutics Market
10.2.6.1.1 Germany Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.2.6.1.2 Germany Small Interfering RNA (siRNA) Therapeutics Market by Types
10.2.6.1.3 Germany Small Interfering RNA (siRNA) Therapeutics Market by End User
10.2.6.2 France Small Interfering RNA (siRNA) Therapeutics Market
10.2.6.2.1 France Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.2.6.2.2 France Small Interfering RNA (siRNA) Therapeutics Market by Types
10.2.6.2.3 France Small Interfering RNA (siRNA) Therapeutics Market by End User
10.2.6.3 Italy Small Interfering RNA (siRNA) Therapeutics Market
10.2.6.3.1 Italy Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.2.6.3.2 Italy Small Interfering RNA (siRNA) Therapeutics Market by Types
10.2.6.3.3 Italy Small Interfering RNA (siRNA) Therapeutics Market by End User
10.2.6.4 Spain Small Interfering RNA (siRNA) Therapeutics Market
10.2.6.4.1 Spain Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.2.6.4.2 Spain Small Interfering RNA (siRNA) Therapeutics Market by Types
10.2.6.4.3 Spain Small Interfering RNA (siRNA) Therapeutics Market by End User
10.2.6.5 United Kingdom Small Interfering RNA (siRNA) Therapeutics Market
10.2.6.5.1 United Kingdom Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.2.6.5.2 United Kingdom Small Interfering RNA (siRNA) Therapeutics Market by Types
10.2.6.5.3 United Kingdom Small Interfering RNA (siRNA) Therapeutics Market by End User
10.2.6.6 Rest of Europe Small Interfering RNA (siRNA) Therapeutics Market
10.2.6.6.1 Rest of Europe Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.2.6.6.2 Rest of Europe Small Interfering RNA (siRNA) Therapeutics Market by Types
10.2.6.6.3 Rest of Europe Small Interfering RNA (siRNA) Therapeutics Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Overview
10.3.2 Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Indication
10.3.4 Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Types
10.3.5 Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Small Interfering RNA (siRNA) Therapeutics Market
10.3.6.1.1 Australia Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.3.6.1.2 Australia Small Interfering RNA (siRNA) Therapeutics Market by Types
10.3.6.1.3 Australia Small Interfering RNA (siRNA) Therapeutics Market by End User
10.3.6.2 China Small Interfering RNA (siRNA) Therapeutics Market
10.3.6.2.1 China Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.3.6.2.2 China Small Interfering RNA (siRNA) Therapeutics Market by Types
10.3.6.2.3 China Small Interfering RNA (siRNA) Therapeutics Market by End User
10.3.6.3 India Small Interfering RNA (siRNA) Therapeutics Market
10.3.6.3.1 India Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.3.6.3.2 India Small Interfering RNA (siRNA) Therapeutics Market by Types
10.3.6.3.3 India Small Interfering RNA (siRNA) Therapeutics Market by End User
10.3.6.4 Japan Small Interfering RNA (siRNA) Therapeutics Market
10.3.6.4.1 Japan Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.3.6.4.2 Japan Small Interfering RNA (siRNA) Therapeutics Market by Types
10.3.6.4.3 Japan Small Interfering RNA (siRNA) Therapeutics Market by End User
10.3.6.5 South Korea Small Interfering RNA (siRNA) Therapeutics Market
10.3.6.5.1 South Korea Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.3.6.5.2 South Korea Small Interfering RNA (siRNA) Therapeutics Market by Types
10.3.6.5.3 South Korea Small Interfering RNA (siRNA) Therapeutics Market by End User
10.3.6.6 Rest of Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market
10.3.6.6.1 Rest of Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.3.6.6.2 Rest of Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market by Types
10.3.6.6.3 Rest of Asia-Pacific Small Interfering RNA (siRNA) Therapeutics Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market Overview
10.4.2 Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Indication
10.4.4 Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Types
10.4.5 Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Small Interfering RNA (siRNA) Therapeutics Market
10.4.6.1.1 South Africa Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.4.6.1.2 South Africa Small Interfering RNA (siRNA) Therapeutics Market by Types
10.4.6.1.3 South Africa Small Interfering RNA (siRNA) Therapeutics Market by End User
10.4.6.2 Saudi Arabia Small Interfering RNA (siRNA) Therapeutics Market
10.4.6.2.1 Saudi Arabia Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.4.6.2.2 Saudi Arabia Small Interfering RNA (siRNA) Therapeutics Market by Types
10.4.6.2.3 Saudi Arabia Small Interfering RNA (siRNA) Therapeutics Market by End User
10.4.6.3 U.A.E Small Interfering RNA (siRNA) Therapeutics Market
10.4.6.3.1 U.A.E Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.4.6.3.2 U.A.E Small Interfering RNA (siRNA) Therapeutics Market by Types
10.4.6.3.3 U.A.E Small Interfering RNA (siRNA) Therapeutics Market by End User
10.4.6.4 Rest of Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market
10.4.6.4.1 Rest of Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.4.6.4.2 Rest of Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market by Types
10.4.6.4.3 Rest of Middle East and Africa Small Interfering RNA (siRNA) Therapeutics Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Small Interfering RNA (siRNA) Therapeutics Market Overview
10.5.2 South and Central America Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Indication
10.5.4 South and Central America Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Types
10.5.5 South and Central America Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By End User
10.5.6 South and Central America Small Interfering RNA (siRNA) Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Small Interfering RNA (siRNA) Therapeutics Market
10.5.6.1.1 Brazil Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.5.6.1.2 Brazil Small Interfering RNA (siRNA) Therapeutics Market by Types
10.5.6.1.3 Brazil Small Interfering RNA (siRNA) Therapeutics Market by End User
10.5.6.2 Argentina Small Interfering RNA (siRNA) Therapeutics Market
10.5.6.2.1 Argentina Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.5.6.2.2 Argentina Small Interfering RNA (siRNA) Therapeutics Market by Types
10.5.6.2.3 Argentina Small Interfering RNA (siRNA) Therapeutics Market by End User
10.5.6.3 Rest of South and Central America Small Interfering RNA (siRNA) Therapeutics Market
10.5.6.3.1 Rest of South and Central America Small Interfering RNA (siRNA) Therapeutics Market by Indication
10.5.6.3.2 Rest of South and Central America Small Interfering RNA (siRNA) Therapeutics Market by Types
10.5.6.3.3 Rest of South and Central America Small Interfering RNA (siRNA) Therapeutics Market by End User

11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. SMALL INTERFERING RNA (SIRNA) THERAPEUTICS MARKET, KEY COMPANY PROFILES
12.1. HORIZON DISCOVERY
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. GLAXOSMITHKLINE
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. SIRNA THERAPEUTICS, INC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ALNYLAM PHARMACEUTICALS
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. SANOFI GENZYME
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. OLIX PHARMACEUTICALS
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. SILENCE THERAPEUTICS AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. CALANDO PHARMACEUTICALS
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. ARBUTUS BIOPHARMA CORP
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SYLENTIS S.A.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments

13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Horizon Discovery
2. GlaxoSmithKline
3. Sirna Therapeutics, Inc.
4. Alnylam Pharmaceuticals
5. Sanofi Genzyme
6. Olix Pharmaceuticals
7. Silence Therapeutics AG
8. Calando Pharmaceuticals
9. Arbutus Biopharma Corp
10. Sylentis S.A.
TIPRE00008765
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.